发明名称 SUSTAINED RELEASE FORMULATION CONTAINING DFMO
摘要 Preparations comprising a capsule, tablet or other dosage form containing a core of different types of DFMO are provided. These preparations are capable of providing for the direct and constant delivery of DFMO to the entire GI tract or just the colon and rectum. The DFMO-containing granules include granules specially formulated to achieve rapid DFMO release, and granules formulated to achieve slower DFMO release and/or granules formulated for gastric, enteric or colorectal release. Methods of using the preparations to flood the GI tract with relatively constant levels of DFMO may thus be provided. The ratio of the (+) to the (-)-enantiomeric forms of DFMO in the granules will be controlled so as to enhance the pharmacological profile and reduce toxicity of the preparation relative to racemic DFMO. Preparations and methods for achieving systemic delivery as well as direct colon delivery of DFMO are also described.
申请公布号 CA2241896(A1) 申请公布日期 1998.05.14
申请号 CA19972241896 申请日期 1997.10.31
申请人 ILEX ONCOLOGY, INC. 发明人 WEIS, ALEXANDER;MCGINITY, JAMES
分类号 A61K9/16;A61K9/20;A61K9/24;A61K9/26;A61K9/48;A61K9/50;A61K31/00;A61K31/195;A61K31/198;A61P35/00;(IPC1-7):A61K31/195;A61K9/22;A61K9/28;A61K9/52 主分类号 A61K9/16
代理机构 代理人
主权项
地址